I received a very touching email from one of our employees a few weeks ago. Key is a technical writer in Northridge, and is currently on the MiniMed 670G system as part of the Customer Training Phase. Key has graciously agreed to allow me to share his experience with you; I hope you find his story as inspirational as I do.
As a 57-year member of the type 1 “clan” – I joined when I was three – I’ve become increasingly more reliant on Medtronic Diabetes to provide cutting-edge technologies to contradict all the negative predictions doctors in the 1960s and 1970s kept giving my parents. “You’ll be lucky to have him until he’s 10.” “He’ll never make it past 20.” “They never live beyond 30 years with this disease.”
Sometimes, the doctors were nearly proven right; wildly fluctuating blood sugars, going clammy and unresponsive in the middle of the night, EMT resuscitations, blackouts behind the wheel, three car crashes, and numerous other embarrassing events. These are my “It was my diabetes acting up” stories.
In 1993, just one year into my marriage – and with a very concerned wife who had not realized what marrying a person with diabetes meant – I started on the MiniMed 506 insulin pump. Very quickly, we found ourselves sleeping soundly through the night. I woke up with blood sugars that were more “normal” and had more energy, enthusiasm, and confidence about taking the wheel on road trips and in everyday life.
In 2004, I started on the Guardian continuous glucose monitoring (CGM) system, and my A1Cs became “healthy.” Several of the diabetes complications began to dissipate. I had even more energy, enthusiasm and hope – and longer life prospects than I had ever imagined.
I can’t even imagine the world of possibilities that being on the MiniMed 670G system will open for me. I may just have to write to some of those doctors, if they’re still alive.
For those “old fogey” people with diabetes who think they are not capable of adjusting to this “new-tech” insulin pump, I would like to say: It’s definitely worth the trouble. I was on the MiniMed 630G system for three months; it was easier to learn than my iPhone. I think the MiniMed 670G system may be the easiest-to-learn insulin pump ever invented!
In my nearly four years at Medtronic Diabetes, I have witnessed a major transformation in our business. We’ve gone from being a 1990s-style, Western-world, pump-and-sensor company, to being a worldwide leader in multiple, innovative diabetes-management therapies.
I am so incredibly proud – and grateful – to be a part of that transformation. Both as an employee, and as a user of our newest system.
Editor’s Note: Until April 28, MiniMed 630G system users can sign up to be first in line to receive the new system for as low as $0 (exclusions apply) as it becomes available through our Priority Access program. Experience on the new pump platform will help facilitate an optimal transition.
Important Safety Information
The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products.
Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.
For complete safety information, please consult the appropriate User Guide.
Tags: customer training phase
, diabetes innovation
, diabetes technology
, Guardian Sensor 3
, hybrid closed loop
, MiniMed 670G system
, priority access program